Skip to main content

Table 1 Patients Demographic Data

From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

Characteristics

Placebo/Routine Care

Levamisole/ Routine Care

Sex, No. (%)

 Male

13 (52.0)

17 (68.0%)

 Female

12 (48.0)

8 (32.0%)

Age, median (IQR), y

 

32.0 (15)

30.0 (14)

Weight, median (IQR), kg

 

70.0 (18)

74.0 (18)

Marital status, No. (%)

 Single

6 (24.0)

6 (24.0)

 Married

19 (76.0)

19 (76.0)

Smoking, No. (%)

 Yes

2 (8.0)

4 (16.0)

 No

23 (92.0)

21 (84.0)

Mean of room-air O2 Sats, %

 

96.50

96.33

Lung CT-Scan involvement, No. (%)

 Positive

22 (88.0)

22 (88.0)

 Negative

0 (0.0)

2 (8.0)

 None

3 (12.0)

1 (4.0)

Lung CT-Scan involvement Score, %

 

2.50

2.75

PCR, No. (%)

 Positive

24 (96.0)

22 (88.0)

 Negative

1 (4.0)

3 (12.0)

Coexisting conditions, No. (%)

 Cardiovascular disease

1 (4.0)

0 (0.0)

 Hypertension

2 (8.0)

1 (4.0)

 Diabetes

3 (12.0)

1 (4.0)

 Asthma

0 (0.0)

2 (8.0)

 Hypothyroidism

1 (4.0)

0 (0.0)

  1. No Number, y year, kg kilogram, O2 Sats oxygen saturation, CT-Scan Computed Tomography Scan, CT involvement Score Scoring the severity by the percentages of each of the five lobes that is involved: 1 for < 5%, 2 for 5–25%, 3 for 26–49%, 4 for 50–75%, and > 75% involvement. The total score is the sum of the individual lobar scores [19], PCR polymerase chain reaction